GlassScriptPhysician profile
Jeffrey B Mccrary
NPI 1245438860
$2,914.40
in general payments reported to CMS, 2019-2025
23 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $170 · 2021: $517 · 2022: $550 · 2023: $433 · 2024: $664 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.29 | 2019-2025 | |
| Boston Scientific Corporation | $441.01 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $399.84 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.25 | 2019-2023 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $141.82 | 2022-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $133.42 | 2024 | Rezdiffra |
| Medtronic, INC. | $133.13 | 2024 | Gi Genius |
| Phathom Pharmaceuticals, INC. | $119.29 | 2023-2025 | Voquezna |
| Mauna Kea Technologies, INC. | $108.82 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $91.56 | 2022 | |
| Celgene Corporation | $82.86 | 2022-2024 | Zeposia |
| Genzyme Corporation | $53.34 | 2024-2025 | |
| Pfizer INC. | $52.73 | 2019 | |
| Merck Sharp & Dohme LLC | $43.07 | 2023-2024 | Dificid |
| Janssen Biotech, INC. | $36.91 | 2019-2025 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $33.91 | 2020 | |
| Ironwood Pharmaceuticals, INC | $28.05 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $22.11 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.21 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $13.12 | 2023 | Rebyota |
| Alexion Pharmaceuticals, INC. | $12.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,382.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.